Original Publication Date: 22 August, 2016
Publication / Source: Biomarkers in Medicine
Authors: Bhatnagar B, Garzon R
Acute myeloid leukemia (AML) is a clinically, biologically, molecularly diverse and highly aggressive hematologic malignancy characterized by clonal expansion of immature myeloid precursors, or blasts, in the blood and bone marrow. Despite current treatments, the long-term overall survival (OS) rates are only approximately 40% for younger (<60 years) and approximately 10% for older (>60 years) AML patients .